Novartis Gets CDSCO Panel nod to study antimalarial drug KLU156 with Coartem Dr. Divya Colin14 Jan 2024 6:00 PM ISTNew Delhi: The drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Novartis drops pursuit of Cytokinetics: Source Ruchika Sharma12 Jan 2024 4:00 PM ISTBasel: Swiss drugmaker Novartis has backed away from its pursuit of Cytokinetics, a person familiar with the matter told Reuters, and the...
Isomorphic Labs inks multi-target research collaboration with Novartis Ruchika Sharma12 Jan 2024 10:00 AM ISTLondon: Isomorphic Labs, a digital biology company has announced that it has entered into a strategic research collaboration with Novartis to...
Novartis in advanced talks to buy Cytokinetics: Source Ruchika Sharma10 Jan 2024 3:30 PM ISTAccess to Cytokinetics products would help Novartis offset the expected loss of U.S. exclusivity of Entresto, its key drug in this field, said...
CDSCO Panel Grants Novartis Protocol Amendment Proposal For Alpelisib Dr. Divya Colin7 Jan 2024 5:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Novartis expands production of Pluvicto with addition of its largest, most advanced radioligand therapy manufacturing facility in Indianapolis Ruchika Sharma7 Jan 2024 2:30 PM ISTBasel: Novartis has announced that it has received approval from the US Food and Drug Administration (FDA) for commercial manufacturing of...
Voyager Therapeutics enters Capsid license agreement with Novartis to advance novel gene therapies Ruchika Sharma3 Jan 2024 2:37 PM ISTUnder the terms of the agreement, Novartis has agreed to pay Voyager $100 million of consideration up front, including a $20 million purchase of newly...
CDSCO Panel Approves AstraZeneca's Proposal for Protocol Amendment of anti-cancer drug Asciminib Dr. Divya Colin2 Jan 2024 5:30 AM ISTNew Delhi: The drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
CDSCO Panel Grants Novartis Protocol Amendment For Ofatumumab Dr. Divya Colin31 Dec 2023 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Novartis Gets CDSCO Panel Nod to study Iptacopan Dr. Divya Colin23 Dec 2023 6:00 PM ISTNew Delhi: In response to the proposal presented by the drug major Novartis, the Subject Expert Committee (SEC) functional under the Central Drug...
JB Pharma enters Opthalmology space, signs Rs 1,089 crore deal with Novartis for 10 brands Ruchika Sharma20 Dec 2023 11:14 AM ISTNew Delhi: JB Chemicals & Pharmaceuticals Ltd (JB Pharma) has announced that the Company has inked a trade mark licence agreement along with...
FDA approves Fabhalta as oral treatment for paroxysmal nocturnal hemoglobinuria Jacinthlyn Sylvia11 Dec 2023 11:15 AM ISTThe US Food and Drug Administration has approved Fabhalta (iptacopan) as first oral monotherapy for adults suffering from paroxysmal nocturnal...
